Search - tctmd.com

Displaying 1 - 20 of 87

Sort: Relevancy | Date

News Daily News

Year in Review: Top Prevention Stories of 2025

Michael O'Riordan

December 24, 2025

News Daily News

Evolocumab Wins for Primary Prevention in VESALIUS-CV

L.A. McKeown

October 03, 2025

News Conference News ESC 2025

NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure

Michael O'Riordan

September 04, 2025

News Daily News

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Michael O'Riordan

June 04, 2025

News Daily News

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Michael O'Riordan

April 22, 2025

News Daily News

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Michael O'Riordan

February 05, 2025

News Conference News ESC 2024

Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events

Michael O'Riordan

September 01, 2024

News Daily News

High-Risk ‘Clues’ Add Heft to Calcium Scores in Primary Prevention

Michael O'Riordan

February 29, 2024

News Daily News

Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER

Michael O'Riordan

February 08, 2024

News Daily News

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Michael O'Riordan

December 06, 2023

News Conference News AHA 2023

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

Shelley Wood

November 13, 2023

News Daily News

Aggressive Lipid-Lowering Very Unlikely to Hurt the Brain: AHA

Todd Neale

September 19, 2023

News Conference News ESC 2023

ORION-8: Safe and Durable Longer-Term LDL-Lowering With Inclisiran

Michael O'Riordan

September 01, 2023

News Daily News

Popliteal Interventions Linked to Higher Long-term Amputation Risk Than SFA

L.A. McKeown

July 11, 2023

News Daily News

LDL Control Remains Poor in CAD Patients: NHANES

Michael O'Riordan

July 05, 2023

News Conference News ACC 2023

Stable CAD Plaque Morphology Improved by PCSK9 Inhibitors: YELLOW III

Shelley Wood

March 04, 2023

News Conference News ACC 2023

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Michael O'Riordan

March 04, 2023

News Daily News

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

Michael O'Riordan

January 16, 2023

News Daily News

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

Michael O'Riordan

January 05, 2023

News Conference News ESC 2022

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

Michael O'Riordan

August 31, 2022

Advertisement

Year in Review: Top Prevention Stories of 2025

Evolocumab Wins for Primary Prevention in VESALIUS-CV

NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events

High-Risk ‘Clues’ Add Heft to Calcium Scores in Primary Prevention

Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

Aggressive Lipid-Lowering Very Unlikely to Hurt the Brain: AHA

ORION-8: Safe and Durable Longer-Term LDL-Lowering With Inclisiran

Popliteal Interventions Linked to Higher Long-term Amputation Risk Than SFA

LDL Control Remains Poor in CAD Patients: NHANES

Stable CAD Plaque Morphology Improved by PCSK9 Inhibitors: YELLOW III

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content